fitm1l Antibody

What is IFITM1 and what is its biological significance?

IFITM1 is an interferon-induced transmembrane protein that functions as a potent antiviral effector. It inhibits viral entry into host cell cytoplasm by permitting endocytosis while preventing subsequent viral fusion and content release into the cytosol. The protein is expressed in various tissues including the respiratory tract, gastrointestinal tract, and immune system, where it plays a crucial role in defending against pathogenic infections . Beyond its antiviral functions, IFITM1 is also implicated in cell adhesion and control of cell growth and migration, making it a multifunctional protein with significant biological importance .

How does IFITM1 differ from other IFITM family members?

While IFITM family proteins (IFITM1, IFITM2, and IFITM3) share high amino acid homology and similar structural features—including two hydrophobic membrane-associated domains (M1 and M2) separated by a conserved intracellular loop (CIL)—they differ in their terminal domains. IFITM2 and IFITM3 contain 20 and 21 amino acid extensions at the N-terminal domain respectively, whereas IFITM1 contains a 13-amino acid extension at the C terminus . These structural differences contribute to their distinct subcellular localizations and functions. In hepatocytes, IFITM1 localizes predominantly to the cell surface with some intracellular presence, while IFITM2 and IFITM3 are found in specific intracellular compartments within the cytoplasm .

What viral pathogens does IFITM1 protect against?

IFITM1 demonstrates broad antiviral activity against multiple pathogens. Research has established its effectiveness against influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), and hepatitis C virus (HCV) . It specifically inhibits influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry . Additionally, it prevents SARS-CoV-2 S protein-mediated syncytia formation, highlighting its potential relevance in COVID-19 research .

What types of IFITM1 antibodies are available for research applications?

Researchers have access to several types of IFITM1 antibodies, each with specific applications and advantages. Current options include rabbit recombinant monoclonal antibodies such as EPR22620-12 (ab233545) and rabbit polyclonal antibodies (ab224063) . These antibodies differ in their production methods, epitope recognition, and optimal experimental applications. Monoclonal antibodies offer high specificity and reproducibility, making them suitable for precise detection of IFITM1 in complex samples. Polyclonal antibodies recognize multiple epitopes on the IFITM1 protein, potentially providing stronger signals in certain applications but with potential for increased background .

How should researchers validate IFITM1 antibody specificity before experimental use?

Validating antibody specificity is crucial for obtaining reliable research results. For IFITM1 antibodies, researchers should employ multiple validation strategies including:

• Positive and negative control samples: Use cell lines with known IFITM1 expression levels and those with IFITM1 knockdown or knockout.

• Cross-reactivity testing: Verify minimal cross-reactivity with other IFITM family members (IFITM2 and IFITM3) which share significant sequence homology.

• Knockdown validation: Confirm reduced signal in samples where IFITM1 has been knocked down using shRNA or siRNA approaches .

• Multiple detection techniques: Compare results across different methods (e.g., Western blot, immunofluorescence, flow cytometry) to confirm consistency.

• Binding site characterization: When possible, verify the specific epitope recognized by the antibody to ensure it doesn't overlap with regions involved in protein-protein interactions.

What are the primary technical considerations when choosing between monoclonal and polyclonal IFITM1 antibodies?

When selecting between monoclonal and polyclonal IFITM1 antibodies, researchers should consider:

• Experimental application: Monoclonal antibodies (e.g., EPR22620-12) are optimal for applications requiring high specificity and reproducibility, including IP, WB, ICC/IF, Flow Cytometry, and IHC-P . Polyclonal antibodies may provide stronger signals in certain applications like IHC-P, WB, and ICC/IF but may have higher background .

• Epitope accessibility: Consider whether the target epitope may be masked in certain experimental conditions. Polyclonal antibodies recognize multiple epitopes, potentially improving detection when some epitopes are obscured.

• Protein modifications: If studying post-translationally modified IFITM1, verify that the antibody's epitope doesn't overlap with modification sites.

• Experimental systems: Confirm that the antibody has been validated in your specific experimental system (e.g., human samples) .

• Detection method: For fluorescence-based approaches, consider antibodies specifically validated for such applications to ensure optimal signal-to-noise ratios.

What experimental conditions optimize IFITM1 antibody performance in immunofluorescence studies?

For optimal immunofluorescence results with IFITM1 antibodies, researchers should consider the following methodological approaches:

• Fixation method: Since IFITM1 is a membrane protein, test both paraformaldehyde (4%) and methanol fixation to determine which better preserves epitope accessibility while maintaining cellular architecture.

• Permeabilization: Use mild detergents (0.1-0.2% Triton X-100 or 0.1% saponin) to maintain membrane integrity while allowing antibody access.

• Blocking conditions: Implement robust blocking (5-10% normal serum from the secondary antibody species) to minimize non-specific binding, particularly important when using polyclonal antibodies.

• Antibody concentration: Carefully titrate primary antibodies to determine optimal concentration that maximizes specific signal while minimizing background.

• Incubation parameters: For membrane proteins like IFITM1, extended primary antibody incubation periods (overnight at 4°C) may improve detection compared to shorter incubations.

• Co-localization studies: When examining IFITM1's subcellular distribution, use established markers for plasma membrane, endosomes, and lysosomes to confirm its predominantly cell surface localization with some intracellular presence, distinguishing it from the primarily intracellular IFITM2 and IFITM3 .

How can researchers effectively analyze IFITM1's role in viral infection using antibody-based approaches?

To effectively investigate IFITM1's antiviral functions, researchers can implement these antibody-dependent experimental strategies:

• Infection timing analysis: Utilize IFITM1 antibodies in time-course experiments to track protein expression and localization before and after viral challenge.

• Co-localization with viral components: Perform dual immunostaining with IFITM1 antibodies and antibodies against viral proteins to assess potential interactions or spatial relationships during different infection stages.

• Loss-of-function studies: Combine IFITM1 knockdown approaches (e.g., shRNA) with antibody detection of viral proteins to quantify effects on viral entry and replication .

• Gain-of-function approaches: In cells overexpressing IFITM1, use antibodies to confirm expression and track the protein's effect on viral infection markers.

• Phosphorylation status: Employ phospho-specific antibodies to examine how post-translational modifications of IFITM1 might regulate its antiviral activity.

• Interaction partners: Use IFITM1 antibodies in co-immunoprecipitation experiments followed by mass spectrometry to identify novel interaction partners during viral infection.

What methodological approaches can distinguish IFITM1 from other IFITM family members in experimental systems?

Distinguishing between highly homologous IFITM family members requires careful methodological considerations:

• Epitope-specific antibodies: Select antibodies targeting the C-terminal region of IFITM1, which differs from IFITM2 and IFITM3, which instead have extended N-termini .

• Subcellular localization analysis: Use high-resolution microscopy with IFITM1 antibodies to leverage the distinct localization patterns—IFITM1 predominantly at the plasma membrane versus the intracellular compartmentalization of IFITM2 and IFITM3 .

• Selective knockdown validation: Implement targeted knockdown of each IFITM family member individually and assess antibody reactivity to confirm specificity.

• Expression systems with tags: When studying overexpressed proteins, use differentially tagged versions (e.g., FLAG-tagged IFITM1) with tag-specific antibodies for unambiguous identification .

• Sequential immunoprecipitation: For complex samples, deplete IFITM2/3 first, then detect remaining IFITM1 to minimize cross-reactivity issues.

How should researchers quantify IFITM1 expression levels in different experimental contexts?

Accurate quantification of IFITM1 expression requires rigorous analytical approaches:

• Western blot quantification: Normalize IFITM1 band intensity to established housekeeping proteins (GAPDH, β-actin) and include standard curves with recombinant IFITM1 protein for absolute quantification.

• Flow cytometry analysis: When using anti-IFITM1 antibodies for flow cytometry, employ quantitative approaches such as molecules of equivalent soluble fluorophore (MESF) or antibody binding capacity (ABC) to convert fluorescence intensity to actual protein numbers.

• RT-qPCR correlation: Correlate protein levels detected by antibodies with mRNA expression measured by RT-qPCR to validate findings across methodologies and identify potential post-transcriptional regulation.

• Image analysis for immunofluorescence: Use automated image analysis software with consistent thresholding parameters to quantify fluorescence intensity and subcellular distribution patterns.

• Induction ratios: When studying interferon responses, calculate fold-change in IFITM1 expression following stimulation rather than absolute values to account for baseline variations between experimental systems.

• Single-cell analysis: Consider the heterogeneity in IFITM1 expression across cell populations by analyzing distributions rather than population averages, particularly in primary cell systems.

What are the potential artifacts and pitfalls when interpreting IFITM1 antibody-based experimental results?

Researchers should be aware of several potential artifacts when working with IFITM1 antibodies:

• Cross-reactivity with IFITM2/3: Due to high sequence similarity among IFITM family members, antibodies may detect multiple proteins, leading to misinterpretation of specificity. Researchers should validate antibody specificity using knockout/knockdown controls .

• Overexpression artifacts: Artificially high IFITM1 expression may cause protein mislocalization or aggregation, creating subcellular distribution patterns that do not reflect physiological reality.

• Fixation-dependent epitope masking: Different fixation methods can alter epitope accessibility, potentially giving inconsistent results across experimental preparations.

• Post-translational modifications: Antibodies may have differential recognition of modified forms of IFITM1, leading to underestimation of total protein levels if modifications are present.

• Background in specific tissues: Some tissues may show higher non-specific binding with certain antibody preparations, requiring careful optimization of blocking conditions and concentration.

• Interferon-induced proteins: When studying interferon-stimulated cells, remember that multiple IFITM family members are upregulated simultaneously, complicating specific attribution of effects to IFITM1 alone .

How can researchers reconcile contradictory findings regarding IFITM1 function from different antibody-based studies?

When faced with contradictory results across studies using IFITM1 antibodies, consider these analytical approaches:

• Antibody specificity assessment: Compare the specific antibodies used across studies—differences in epitope recognition, format (monoclonal vs. polyclonal), and validation methods may explain discrepancies.

• Cell type considerations: IFITM1 may function differently across cell types due to varying expression levels, interaction partners, or post-translational modifications. Analyze whether contradictory findings stem from experiments in different cellular contexts.

• Methodological differences: Evaluate how differences in experimental conditions (fixation, permeabilization, detection methods) might impact results.

• Interferon stimulation status: Confirm whether studies were conducted under basal conditions or after interferon stimulation, which dramatically alters IFITM1 expression levels and potentially function .

• Orthogonal validation: Implement complementary approaches that don't rely on antibodies (e.g., CRISPR knockout, tagged protein expression) to independently verify findings.

• Meta-analysis approaches: When possible, perform quantitative comparisons across multiple studies to identify consistent patterns despite methodological variations.

How can IFITM1 antibodies be integrated into high-throughput screening approaches for antiviral drug discovery?

IFITM1 antibodies can enhance antiviral drug discovery through these advanced screening approaches:

• High-content imaging platforms: Utilize fluorescently labeled IFITM1 antibodies in automated microscopy systems to screen compound libraries for molecules that enhance IFITM1 expression or alter its subcellular distribution in ways that might potentiate antiviral activity.

• Flow cytometry-based screening: Develop high-throughput flow cytometry protocols using anti-IFITM1 antibodies to rapidly assess IFITM1 expression changes across large treatment groups.

• IFITM1 functional readouts: Create reporter systems where IFITM1 antibodies detect conformational changes or relocalization events associated with antiviral function, providing functional rather than merely expressional readouts.

• Combination screening approaches: Use IFITM1 antibodies alongside viral infection markers to identify compounds that specifically enhance IFITM1-mediated viral restriction rather than generally inducing interferon responses.

• Patient-derived systems: Apply IFITM1 antibody-based detection to patient-derived cells to identify individuals who might benefit from therapies targeting IFITM1 pathways, potentially enabling personalized antiviral approaches.

What novel approaches enable studying dynamic IFITM1 protein interactions during viral entry?

Advanced methodologies to investigate IFITM1's dynamic interactions during viral infection include:

• Live-cell imaging with antibody fragments: Utilize fluorescently labeled single-chain variable fragments (scFvs) derived from IFITM1 antibodies for real-time tracking of protein dynamics during viral challenge.

• Proximity labeling: Combine IFITM1 antibodies with techniques like BioID or APEX2 proximity labeling to identify transient interaction partners specifically during viral entry stages.

• Super-resolution microscopy: Apply IFITM1 antibodies in techniques like STORM or PALM to visualize nanoscale organization of IFITM1 at the plasma membrane and potential reorganization during viral attachment.

• Single-molecule tracking: Employ quantum dot-conjugated IFITM1 antibody fragments to track individual IFITM1 molecules and their diffusion characteristics before and during viral engagement.

• Correlative light-electron microscopy: Use IFITM1 antibodies in CLEM approaches to correlate protein localization with ultrastructural changes in membrane organization during viral entry processes.

• FLIM-FRET analysis: Develop fluorescence lifetime imaging microscopy-based FRET pairs using IFITM1 antibodies to detect conformational changes or protein-protein interactions with nanometer precision.

How can computational approaches enhance IFITM1 antibody design for improved specificity and functionality?

Computational methodologies are revolutionizing antibody design for challenging targets like IFITM1:

• Biophysics-informed modeling: Implement computational models that identify and disentangle multiple binding modes associated with specific epitopes, enabling the prediction and generation of IFITM1-specific antibodies beyond those observed in conventional experiments .

• Epitope mapping optimization: Use structural prediction algorithms to identify unique, accessible epitopes on IFITM1 that differ maximally from IFITM2/3, then design antibodies targeting these regions for improved specificity.

• Antibody engineering for membrane proteins: Apply computational approaches to optimize antibody properties specifically for membrane protein targets, addressing challenges of accessibility and conformation-dependent epitopes common in proteins like IFITM1.

• Machine learning for cross-reactivity prediction: Develop machine learning algorithms that predict potential cross-reactivity with related proteins based on sequence and structural similarities, then use these predictions to guide antibody engineering.

• Phage display integration: Combine computational predictions with phage display experimental data to iteratively improve antibody specificity, using high-throughput sequencing and downstream computational analysis to identify optimal candidates .

• Customized specificity profiles: Utilize computational design approaches to generate IFITM1 antibodies with precisely defined specificity profiles, either with specific high affinity for particular epitopes or with controlled cross-reactivity for multiple targets when desired .

What strategies can address common challenges in IFITM1 detection by Western blotting?

For effective Western blot detection of IFITM1, researchers should consider these troubleshooting approaches:

• Sample preparation optimization: Since IFITM1 is a membrane protein, use specialized lysis buffers containing appropriate detergents (e.g., 1% Triton X-100 or 0.5% NP-40) to ensure efficient extraction while maintaining epitope integrity.

• Heating conditions: Test different sample heating protocols (65°C vs. 95°C) as membrane proteins can form aggregates with excessive heating, leading to smeared bands or signal at unexpected molecular weights.

• Transfer optimization: Employ semi-dry transfer systems or specialized wet transfer protocols optimized for hydrophobic membrane proteins to ensure efficient transfer to membranes.

• Blocking agent selection: Test different blocking agents (BSA vs. non-fat milk) as milk proteins may occasionally interfere with detection of certain membrane protein epitopes.

• Multiple antibody approach: When possible, use antibodies recognizing distinct epitopes to confirm band identity and distinguish IFITM1 (15 kDa) from other family members.

• Loading controls: Select appropriate loading controls for membrane fraction enriched samples, as traditional housekeeping proteins may not accurately represent membrane protein fractions.

How should researchers approach IFITM1 antibody titration for optimal signal-to-noise ratios in different applications?

Systematic antibody titration is essential for optimal IFITM1 detection:

• Application-specific titration ranges:

  • For Western blotting: Test dilutions from 1:500 to 1:5000

  • For immunofluorescence: Evaluate concentrations from 1:100 to 1:1000

  • For flow cytometry: Assess ranges from 1:50 to 1:500

• Titration methodology: Perform serial dilutions of antibody while keeping all other experimental parameters constant, then quantify both specific signal and background to calculate signal-to-noise ratios for each dilution.

• Positive and negative controls: Include IFITM1-overexpressing samples and IFITM1-knockout/knockdown samples in titration experiments to accurately determine specificity at each concentration.

• Cell type considerations: Recognize that optimal antibody concentrations may vary between cell types due to differences in endogenous expression levels, accessibility of epitopes, or potential cross-reactive proteins.

• Secondary antibody matching: Optimize the primary-to-secondary antibody ratio, as excess secondary antibody can increase background while insufficient amounts may limit detection sensitivity.

• Batch testing: When receiving new antibody lots, perform abbreviated titration experiments to confirm that optimal concentrations remain consistent across manufacturing batches.

What alternative approaches can complement or replace antibody-based detection of IFITM1 in challenging experimental contexts?

When antibody-based detection presents limitations, these alternative approaches can be valuable:

• Epitope tagging strategies: Generate cell lines expressing epitope-tagged IFITM1 (FLAG, HA, or V5) and use well-characterized tag antibodies for detection, particularly useful in systems where IFITM1 antibodies show cross-reactivity issues .

• CRISPR/Cas9 knock-in approaches: Insert fluorescent protein tags (GFP, mCherry) directly into the endogenous IFITM1 locus to enable antibody-independent visualization while maintaining native expression regulation.

• Mass spectrometry-based proteomics: Implement targeted proteomics approaches using unique IFITM1 peptides for specific detection and quantification in complex samples.

• RNA-based detection methods: Use RNA-FISH or single-cell RNA sequencing to quantify IFITM1 mRNA as a proxy for protein expression, particularly useful in tissues where antibody penetration is challenging.

• Activity-based protein profiling: Develop activity-based probes that specifically label functional IFITM1, potentially providing information about both expression and functional status.

• Proximity ligation assays: When studying IFITM1 interactions, employ proximity ligation approaches that can provide enhanced specificity through the requirement for dual epitope recognition.